- |||||||||| budesonide / Generic mfg., azathioprine orodispersible / Generic mfg.
Small bowel capsule endoscopy impact on therapeutic decisions in established Crohn’s disease: Analysis of a real-world data (Hall C - Poster exhibition) - Jan 7, 2020 - Abstract #ECCOIBD2020ECCO_IBD_1637;
Significant inflammatory activity (LS ≥ 135), as compared with LS < 135, were also more frequently associate with changes in therapeutic management (82% vs. 25%, p: 0.004).Conclusion In our study, CE in patients with eCD added valuable clinical information and had a great impact on therapeutic decisions. Whether this approach will improve outcomes in eCD will require further investigation.
- |||||||||| Effectiveness of vedolizumab therapy in a real-world setting in Germany: First results of the VEDOibd study comparing vedolizumab to the use of other biologics (Hall C - Poster exhibition) - Jan 7, 2020 - Abstract #ECCOIBD2020ECCO_IBD_1636;
At week 14 we compared clinical response (CD: reduction of Harvey Bradshaw Index [HBI] from baseline to week 14 by >3 points or HBI 3 points or a reduction of at least 30% compared with baseline) and steroid-free remission rates (CD: HBI 0.05) and 60.0%/21.1% vs. 56.0%/13.7% in UC (p>0.05), respectively.Conclusion In this real-world setting we could show that in CD the effectiveness of VEDO vs. other biologics was very similar in bio-naïve patients and that in UC patients, VEDO treatment tended to be numerically superior to other biologics with respect to response and steroid-free remission rates. Further follow-up data of this interim-analysis including the whole planned study population of 1.200 IBD-patients will be shown in the near future.
- |||||||||| budesonide / Generic mfg.
Effects and safety of a colon-long absorbing budesonide product in patients with mild to moderate ulcerative colitis (Hall C - Poster exhibition) - Jan 7, 2020 - Abstract #ECCOIBD2020ECCO_IBD_1342;
One patient had a relapse during the treatment.Conclusion In our study, budesonide-MMX proved to be safe by bringing up a low number of side effects, while more than two-thirds of the patients could reach remission with this short-term therapy. Hormonal changes were not mentionable, although the drug’s effects on serum lipid content have to be examined further.
- |||||||||| Patient-reported outcomes: the ICHOM standard set for IBD in real-life practice helps quantify deficits in current care (Hall C - Poster exhibition) - Jan 7, 2020 - Abstract #ECCOIBD2020ECCO_IBD_1208;
(adalimumab 13%, golimumab <1%, infliximab 9%, tofacitinib 1%, ustekinumab 1%, vedolizumab 16%)...Eighty-two (16%) felt they needed a treatment change, and 136 (27%) felt their current treatment was not useful for their IBD.Conclusion Outcomes reported by patients illustrate the scale of the therapeutic deficit in current care. The ICHOM Standard Set acts as a benchmark for comparing outcomes between institutions.
- |||||||||| budesonide / Generic mfg.
Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker in collagenous colitis (Hall C - Poster exhibition) - Jan 7, 2020 - Abstract #ECCOIBD2020ECCO_IBD_1009;
There is a need for non-invasive diagnostic tools, and this study examines the potential of NGAL as a biomarker in collagenous colitis (CC) as one of the two main histological forms of MC.Methods Gene expression of colonic biopsies (n = 9/group) from active CC, budesonide treated CC in clinical remission and healthy controls (HC) was explored by RNA-sequencing analysis...This is also reflected in the faecal concentrations. We propose NGAL as a valuable biomarker in evaluating the inflammatory activity related to CC and a potential faecal biomarker discriminating CC from IBS-D.
- |||||||||| budesonide / Generic mfg.
Whole-genome RNA sequencing in collagenous colitis: a subgroup analysis (Hall C - Poster exhibition) - Jan 7, 2020 - Abstract #ECCOIBD2020ECCO_IBD_918;
Unique gene expression profiles describe patient sub-populations, which could define budesonide-refractory CC as a distinct disease entity. Further study of the transcriptional landscape of CC may reveal pathogenic mechanisms and therapeutic targets for this common, debilitating inflammatory bowel disease.
- |||||||||| budesonide / Generic mfg.
Journal: Ultrafast star-shaped acoustic micromixer for high throughput nanoparticle synthesis. (Pubmed Central) - Jan 4, 2020
At the optimal frequency, this acoustofluidic system can homogenise two fluids with a relative mixing efficiency of 91%, within 4.1 ms from first contact. The micromixer has been used to synthesize two different systems: Budesonide nanodrugs with an average diameter of 80 ± 22 nm, and DNA nanoparticles with an average diameter of 63.3 ± 24.7 nm.
- |||||||||| budesonide / Generic mfg.
Preclinical, Journal: Effect of methyl eugenol on nasal mucosal aquaporin 5 in rats with allergic rhinitis (Pubmed Central) - Dec 27, 2019
Both budesonide and colesevelam show potential as effective interventions against neratinib-induced diarrhea. Methyl eugenol may increase the degree of edema of the nasal mucosa by reducing the expression of AQP5 and reduce the secretion of glands, thus alleviating the symptoms of allergic rhinitis, sneezing and runny nose.
- |||||||||| budesonide / Generic mfg.
Journal: Role of TRPC1 channels in pressure-mediated activation of airway remodeling. (Pubmed Central) - Dec 26, 2019
TRPC1 inducing abnormal Ca signal mediates receptor-stimulated and mechanical stimulus-induced airway remodeling. The inhibition of TRPC1 channel could produce similar therapeutic effect as glucocortisteroid to curb the development of asthmatic airway remodeling.
- |||||||||| budesonide / Generic mfg.
Retrospective data, Journal: Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis. (Pubmed Central) - Dec 23, 2019
In contrast, compared with budesonide, combined budesonide/formoterol was associated with similar risks of adverse effects, including pneumonia (OR: 1.20, 95% CI: 0.60-2.39), bronchitis (OR: 0.95, 95% CI: 0.41-2.20), oral candidiasis (OR: 0.79, 95% CI: 0.41-1.53), and dysphonia (OR: 1.00, 95% CI: 0.40-2.47). Combination therapy does not cause more adverse events, including pneumonia and bronchitis, than control (placebo, formoterol, or budesonide) treatment in patients with stable COPD, while there were higher risks of oral candidiasis and dysphonia compared with the non-inhaled corticosteroid group (placebo, formoterol).
- |||||||||| budesonide / Generic mfg.
Retrospective data, Journal, Adverse events: The efficacy and adverse effects of budesonide in remission induction treatment of autoimmune hepatitis: a retrospective study. (Pubmed Central) - Dec 23, 2019
This study showed no differences in biochemical response between the groups. Lower, although not significantly, rate of adverse effects and lower total number of adverse effects indicate that BUD/AZA may potentially be used as the first-line treatment of choice, especially in patients with obesity, diabetes, resistant hypertension, glaucoma, or osteoporosis.
- |||||||||| budesonide / Generic mfg., budesonide/salbutamol (PT027) / AstraZeneca, Avillion
Clinical, Journal, Video: Using Video Telehealth to Facilitate Inhaler Training in Rural Patients with Obstructive Lung Disease. (Pubmed Central) - Dec 21, 2019
Reactive airway disease may confound the clinical picture; hence should be thoroughly evaluated for and treated if present. Video telehealth inhaler training using the TTG methodology is a promising program that improved inhaler technique and access to inhaler teaching for rural patients with COPD or asthma.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J
PEDIATRIC CROHN'S DISEASE PRESENTINAG AS GENITAL EDEMA (Exhibit Hall 1 - Austin Convention Center) - Dec 21, 2019 - Abstract #CCCongress2020CCCONGRESS_315;
Topical tacrolimus did not resolve edema...He was treated with budesonide and mesalamine with subsequent improvement in the scrotal edema. Patients presenting as genital edema as their initial Crohn’s presentation is rare and it is important for providers to be aware of this rare manifestation.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Stelara (ustekinumab) / J&J, Entyvio (vedolizumab) / Takeda
LEUKOCYTOCLASTIC VASCULITIS AFTER USTEKINUMAB INDUCTION IN CROHN'S DISEASE: A CASE SERIES AND SYSTEMATIC REVIEW (Exhibit Hall 1 - Austin Convention Center) - Dec 21, 2019 - Abstract #CCCongress2020CCCONGRESS_309;
It is possible to develop LCV in association with CD alone; however, these patients had longstanding disease without occurrence of LCV until being started on UST. Moreover, patient #1, was in remission from a Crohn’s disease standpoint at the time of UST initiation and onset of the rash.
- |||||||||| Tecfidera (dimethyl fumarate) / Biogen, Ocrevus (ocrelizumab) / Roche, Biogen
DE NOVO COLITIS AFTER OCRELIZUMAB THERAPY (Exhibit Hall 1 - Austin Convention Center) - Dec 21, 2019 - Abstract #CCCongress2020CCCONGRESS_306;
To our knowledge, this is the first reported case of colitis associated with ocrelizumab therapy. Pertinent features include a) initial presentation with nonbloody diarrhea and endoscopic pancolitis with elevated ESR, CRP and fecal calprotectin, b) clinical response to prednisone and budesonide, and c) evolution into a collagenous colitis phenotype.
- |||||||||| budesonide / Generic mfg., budesonide ER / Generic mfg.
Journal: A current overview of corticosteroid use in active ulcerative colitis. (Pubmed Central) - Dec 20, 2019
In mild-moderate distal disease topical administration of corticosteroids (both systemic and BDP) is an effective alternative to topical mesalazine. However, corticosteroids do not represent a therapeutic option as a maintenance treatment since they are associated with multiple adverse effects.
- |||||||||| budesonide / Generic mfg.
Journal: Swellable polymeric particles for the local delivery of budesonide in oral mucositis. (Pubmed Central) - Dec 20, 2019
In this work, we propose the development of a biocompatible delivery system with boosted abilities of retention and control release of budesonide, a corticosteroid with an elevated ratio of topical anti-inflammatory to systemic action. Through spray-drying, polymeric particles of Chitosan and Eudragit E PO were produced and characterized for the vectorization of this drug.
- |||||||||| budesonide / Generic mfg., Remaloce (infliximab biosimilar) / Yuhan, Biogen, Ewopharma, Merck (MSD), Samsung
Drug-Induced Liver Injury (DILI) Associated With Anti-tumor Necrosis Factor Alpha (Anti-TNFα) Agent () - Dec 11, 2019 - Abstract #AIBD2019AIBD_65;
Acute liver injury caused by anti-TNFα antagonist may be a class effect since several agents in this category have been implicated. In this case, the most common presentation occurred as an autoimmune phenotype with marked hepatocellular injury.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Microscopic Colitis With Quiescent Crohn’s Disease: A Case Report () - Dec 11, 2019 - Abstract #AIBD2019AIBD_17;
We report a case of Crohn’s disease whose clinical course was complicated by collagenous colitis while on adalimumab...She was placed back on budesonide 9 mg daily which resolved her symptoms of diarrhea...The association between collagenous colitis and IBD is still unclear. In patients with Ulcerative Colitis or Crohn’s disease, the onset of new symptoms of non-bloody diarrhea with no signs of IBD relapse on endoscopy, mucosal biopsies should be obtained to rule out MC.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
Successful Use of Combination Biologic Therapy in Medically Refractory Pediatric Crohn's Disease and Sacroiliitis () - Dec 11, 2019 - Abstract #AIBD2019AIBD_13;
He had sub-optimal clinical improvement on anti-tumor necrosis factor (TNF) therapy that included infliximab for 1 year, followed by adalimumab for 1.5 years...At the time of presentation to our center he was steroid dependent on prednisone 5 mg daily for 6 months while still on vedolizumab and azathioprine...He was treated with Budesonide MMX and mesalamine enemas with no improvement...Adalimumab and oral methotrexate were given in addition to vedolizumab...When used judiciously in patients with medically refractory disease it can be safe and effective. A paucity of literature exists regarding the use of combination biologicals especially in children.
- |||||||||| Anoro Ellipta (umeclidinium + vilanterol) / Innoviva, GSK
Clinical, PK/PD data, Journal: Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD. (Pubmed Central) - Dec 6, 2019
The analyses were conducted in a subset of 74 patients who received fluticason furoate-umeclidinium-vilanterol and provided serial or sparse samples. Monte Carlo simulations and a model-based estimation approach both indicated that systemic drug concentrations of fluticasone furoate, umeclidinium, and vilanterol after administration of fluticason furoate-umeclidinium-vilanterol triple combination therapy from a single inhaler were within the ranges observed following administration of these drugs as monotherapy (fluticasone furoate, umeclidinium, and vilanterol) or as dual-combination therapy (fluticasone furoate/vilanterol or umeclidinium/vilanterol).
- |||||||||| budesonide / Generic Mfg.
Journal: Inhalable co-amorphous budesonide-arginine dry powders prepared by spray drying. (Pubmed Central) - Dec 6, 2019
In addition, the co-amorphous BUD-ARG was more physically stable than spray-dried BUD when stored at room temperature under dry conditions. This study demonstrated that spray drying is a useful manufacturing approach to produce physically stable co-amorphous dry powders for inhalation purposes.
- |||||||||| Clinical, Review, Journal: British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. (Pubmed Central) - Dec 1, 2019
Comprehensive up-to-date guidance is provided regarding indications for, initiation and monitoring of immunosuppressive therapies, nutrition interventions, pre-, peri- and postoperative management, as well as structure and function of the multidisciplinary team and integration between primary and secondary care. Twenty research priorities to inform future clinical management are presented, alongside objective measurement of priority importance, determined by 2379 electronic survey responses from individuals living with ulcerative colitis and Crohn's disease, including patients, their families and friends.
- |||||||||| budesonide / Generic Mfg.
Clinical, Journal, HEOR, Real-World Evidence: Real-World Data on Topical Therapies and Annual Health Resource Utilization in Hospitalized Swiss Patients with Ulcerative Colitis. (Pubmed Central) - Nov 29, 2019
Topical treatment with aminosalicylates and/or budesonide was shown to be highly effective in patients with ulcerative colitis (UC), while reducing the likelihood of systemic adverse effects...Topical treatment is underused in patients with UC, which stands in contrast to the current European Crohn's and Colitis Organization guidelines. Patients' preferences and considerations need to be taken into account when prescribing medical therapy.
- |||||||||| NN1213 / Novo Nordisk
Enrollment change, Trial termination: Eosinophilic Esophagitis Clinical Therapy Comparison Trial (clinicaltrials.gov) - Nov 29, 2019
P2, N=5, Terminated,
Patients' preferences and considerations need to be taken into account when prescribing medical therapy. N=60 --> 5 | Active, not recruiting --> Terminated; Recruitment was below expectation
- |||||||||| budesonide / Generic Mfg.
Journal: Particulate Matter 2.5 Causes Deficiency in Barrier Integrity in Human Nasal Epithelial Cells. (Pubmed Central) - Nov 22, 2019
Exposure to PM2.5 may lead to loss of barrier function in human nasal epithelium through decreased expression of TJ proteins and increased release of proinflammatory cytokines. These results suggest an important mechanism of susceptibility to rhinitis and rhinosinusitis in highly PM2.5-polluted areas.
|
